Background: Antepartum depression, a non-psychotic mood disturbance occurring during pregnancy, is influenced by hormonal fluctuations and environmental endocrine disruptors. Despite its association with adverse postpartum outcomes, it has been studied to a limited extent. Hence, this study aims to investigate the association of neuroactive steroids, endocrine-disrupting compounds, and nutritional status of pregnant women with the manifestations of antepartum depressive symptoms.
Materials And Methods: This cross-sectional study assessed 400 pregnant women in their third trimester for depressive symptoms using the Edinburgh Postnatal Depression Scale (EPDS) and evaluated for severity using the Beck Depression Inventory-II. The concentrations of allopregnanolone, DHEA-S, bisphenol A, methyl paraben, estradiol, progesterone, oxytocin, vitamin B, folic acid, vitamin D, iron, magnesium and zinc were analysed. Statistical analysis included Mann Whitney U test, Chi-square test, Spearman Correlation, and Logistic regression.
Results: The prevalence of antepartum depressive symptoms was 23 %. Allopregnanolone, DHEA-S, bisphenol A, methyl paraben, estradiol, oxytocin, and TSH levels were associated with depressive symptoms. Reduced levels of allopregnanolone, DHEA-S, and estradiol, along with elevated bisphenol A levels, were identified as significant independent risk factors for antepartum depressive symptoms. Selective micronutrient deficiency was also noted. Risk cutoff for antepartum depressive symptoms was established for allopregnanolone (≤17.9 ng/ml), DHEA-S (≤0.20 µg/ml), bisphenol A (≥2027.1 pg/ml), and methyl paraben (≥1.15 µg/ml).
Conclusion: Our study on 400 antepartum women showed a 23 % prevalence of depressive symptoms, with significant association reported with reduced neuroactive steroids, elevated endocrine disruptors, lower reproductive hormones, and micronutrient deficiency. These findings emphasize the need for comprehensive screening, monitored nutritional supplementation, and hormonal assessments in effectively managing pregnancy-related depressive symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuro.2025.02.007 | DOI Listing |
Ann Ig
March 2025
Department of Global Public Health Policy and Governance, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
Background: Seafarers experience unique challenges related to their profession, including risks for mental health. The present study explored the correlates of depression among seafarers in India.
Methods: Following ethics clearance, this cross-sectional study was conducted at an international shipping company in Mumbai, India.
Curr Med Res Opin
March 2025
Merck Healthcare KGaA, Darmstadt, Germany.
Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature.
View Article and Find Full Text PDFFront Pharmacol
February 2025
School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, China.
Atherosclerosis (AS)-related cardiovascular disease and depression are often comorbid, with patients with cardiovascular disease facing an increased risk of depression, which worsens AS. Both diseases are characterized by oxidative stress and lipid metabolism disorders. Ferroptosis, a form of cell death characterized by iron overload and harmful lipid peroxide accumulation, is found in various diseases, including AS and depression.
View Article and Find Full Text PDFPers Med Psychiatry
April 2024
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
Background: We previously identified a cognitive biotype of depression characterized by dysfunction of the brain's cognitive control circuit, comprising the dorsolateral prefrontal cortex (dLPFC) and dorsal anterior cingulate cortex (dACC), derived from functional magnetic resonance imaging (fMRI). We evaluate these circuit metrics as personalized predictors of antidepressant remission.
Methods: We undertook a secondary analysis of data from the international Study to Predict Optimized Treatment in Depression (iSPOT-D) for 159 patients who completed fMRI during a GoNoGo task, 8 weeks treatment with one of three study antidepressants and who were assessed for remission status (Hamilton Depression Rating Scale score of ≤ 7).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!